624 related articles for article (PubMed ID: 32473640)
1. Omega-3 fatty acid exposure with a low-fat diet in patients with past hypertriglyceridemia-induced acute pancreatitis; an exploratory, randomized, open-label crossover study.
Dunbar RL; Gaudet D; Davidson M; Rensfeldt M; Yang H; Nilsson C; Kvarnström M; Oscarsson J
Lipids Health Dis; 2020 May; 19(1):117. PubMed ID: 32473640
[TBL] [Abstract][Full Text] [Related]
2. Effects of Food on the Pharmacokinetics of Omega-3-Carboxylic Acids in Healthy Japanese Male Subjects: A Phase I, Randomized, Open-label, Three-period, Crossover Trial.
Shimada H; Nilsson C; Noda Y; Kim H; Lundström T; Yajima T
J Atheroscler Thromb; 2017 Sep; 24(9):980-987. PubMed ID: 28344197
[TBL] [Abstract][Full Text] [Related]
3. Systemic Bioavailability and Dose Proportionality of Omega-3 Administered in Free Fatty Acid Form Compared With Ethyl Ester Form: Results of a Phase 1 Study in Healthy Volunteers.
Offman E; Davidson M; Abu-Rashid M; Chai P; Nilsson C
Eur J Drug Metab Pharmacokinet; 2017 Oct; 42(5):815-825. PubMed ID: 28116646
[TBL] [Abstract][Full Text] [Related]
4. Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study.
Offman E; Marenco T; Ferber S; Johnson J; Kling D; Curcio D; Davidson M
Vasc Health Risk Manag; 2013; 9():563-73. PubMed ID: 24124374
[TBL] [Abstract][Full Text] [Related]
5. A Single-dose, Comparative Bioavailability Study of a Formulation containing OM3 as Phospholipid and Free Fatty Acid to an Ethyl Ester Formulation in the Fasting and Fed States.
Lapointe JF; Harvey L; Aziz S; Jordan H; Hegele RA; Lemieux P
Clin Ther; 2019 Mar; 41(3):426-444. PubMed ID: 30799231
[TBL] [Abstract][Full Text] [Related]
6. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: the ECLIPSE (Epanova(®) compared to Lovaza(®) in a pharmacokinetic single-dose evaluation) study.
Davidson MH; Johnson J; Rooney MW; Kyle ML; Kling DF
J Clin Lipidol; 2012; 6(6):573-84. PubMed ID: 23312053
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of Single and Multiple Doses of Omega-3 Carboxylic Acids in Healthy Chinese Subjects: A Phase I, Open-Label Study.
Jing S; Zhang Z; Chen X; Miao R; Nilsson C; Lin Y
Clin Pharmacol Drug Dev; 2020 Nov; 9(8):985-994. PubMed ID: 32567203
[TBL] [Abstract][Full Text] [Related]
8. Effects of a Self-micro-emulsifying Delivery System Formulation Versus a Standard ω-3 Acid Ethyl Ester Product on the Bioavailability of Eicosapentaenoic Acid and Docosahexaenoic Acid: A Study in Healthy Men and Women in a Fasted State.
Maki KC; Palacios OM; Buggia MA; Trivedi R; Dicklin MR; Maki CE
Clin Ther; 2018 Dec; 40(12):2065-2076. PubMed ID: 30454850
[TBL] [Abstract][Full Text] [Related]
9. A Novel ω-3 Acid Ethyl Ester Formulation Incorporating Advanced Lipid Technologies
Lopez-Toledano MA; Thorsteinsson T; Daak A; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
Clin Ther; 2017 Mar; 39(3):581-591. PubMed ID: 28189364
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of OM3-PL/FFA Pharmacokinetics After Single and Multiple Oral Doses in Healthy Volunteers.
Lapointe JF; Harvey L; Aziz S; Hegele RA; Lemieux P
Clin Ther; 2019 Dec; 41(12):2500-2516. PubMed ID: 31679821
[TBL] [Abstract][Full Text] [Related]
11. A novel self-micro-emulsifying delivery system (SMEDS) formulation significantly improves the fasting absorption of EPA and DHA from a single dose of an omega-3 ethyl ester concentrate.
Qin Y; Nyheim H; Haram EM; Moritz JM; Hustvedt SO
Lipids Health Dis; 2017 Oct; 16(1):204. PubMed ID: 29037249
[TBL] [Abstract][Full Text] [Related]
12. A Head-to-Head Comparison of a Free Fatty Acid Formulation of Omega-3 Pentaenoic Acids Versus Icosapent Ethyl in Adults With Hypertriglyceridemia: The ENHANCE-IT Study.
Maki KC; Bays HE; Ballantyne CM; Underberg JA; Kastelein JJP; Johnson JB; Ferguson JJ
J Am Heart Assoc; 2022 Mar; 11(6):e024176. PubMed ID: 35232215
[TBL] [Abstract][Full Text] [Related]
13. Minimal food effect for eicosapentaenoic acid and docosahexaenoic acid bioavailability from omega-3-acid ethyl esters with an Advanced Lipid Technologies
Lopez-Toledano MA; Thorsteinsson T; Daak AA; Maki KC; Johns C; Rabinowicz AL; Sancilio FD
J Clin Lipidol; 2017; 11(2):394-405. PubMed ID: 28502496
[TBL] [Abstract][Full Text] [Related]
14. Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial.
Dunbar RL; Nicholls SJ; Maki KC; Roth EM; Orloff DG; Curcio D; Johnson J; Kling D; Davidson MH
Lipids Health Dis; 2015 Sep; 14():98. PubMed ID: 26328624
[TBL] [Abstract][Full Text] [Related]
15. Similar eicosapentaenoic acid and docosahexaenoic acid plasma levels achieved with fish oil or krill oil in a randomized double-blind four-week bioavailability study.
Yurko-Mauro K; Kralovec J; Bailey-Hall E; Smeberg V; Stark JG; Salem N
Lipids Health Dis; 2015 Sep; 14():99. PubMed ID: 26328782
[TBL] [Abstract][Full Text] [Related]
16. A highly bioavailable omega-3 free fatty acid formulation improves the cardiovascular risk profile in high-risk, statin-treated patients with residual hypertriglyceridemia (the ESPRIT trial).
Maki KC; Orloff DG; Nicholls SJ; Dunbar RL; Roth EM; Curcio D; Johnson J; Kling D; Davidson MH
Clin Ther; 2013 Sep; 35(9):1400-11.e1-3. PubMed ID: 23998969
[TBL] [Abstract][Full Text] [Related]
17. The effect of omega-3 carboxylic acids on apolipoprotein CIII-containing lipoproteins in severe hypertriglyceridemia.
Morton AM; Furtado JD; Lee J; Amerine W; Davidson MH; Sacks FM
J Clin Lipidol; 2016; 10(6):1442-1451.e4. PubMed ID: 27919362
[TBL] [Abstract][Full Text] [Related]
18. Risk stratification by the "EPA+DHA level" and the "EPA/AA ratio" focus on anti-inflammatory and antiarrhythmogenic effects of long-chain omega-3 fatty acids.
Rupp H; Wagner D; Rupp T; Schulte LM; Maisch B
Herz; 2004 Nov; 29(7):673-85. PubMed ID: 15580322
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial comparing omega-3 fatty acid plasma levels after ingestion of emulsified and non-emulsified cod liver oil formulations.
Conus N; Burgher-Kennedy N; van den Berg F; Kaur Datta G
Curr Med Res Opin; 2019 Apr; 35(4):587-593. PubMed ID: 30106311
[TBL] [Abstract][Full Text] [Related]
20. Sex, Body Mass Index, and APOE4 Increase Plasma Phospholipid-Eicosapentaenoic Acid Response During an ω-3 Fatty Acid Supplementation: A Secondary Analysis.
Loukil I; Aguilera EC; Vachon A; Léveillé P; Plourde M
J Nutr; 2024 May; 154(5):1561-1570. PubMed ID: 38513888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
